Company ProfilePremium

Ion Beam Applications S.A.

Company Profile Analysis

Ticker: IBAB.BR

ESOMAR 23 Corporate BadgeISO Certifications Badge
Ion Beam Applications S.A. - Company showcase

Year Founded & Workforce

1986

2,300 Employees

Ion Beam Applications S.A. logo

Ion Beam Applications S.A. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ion Beam Applications S.A. Overview

IBA describes itself as "the world leader in particle accelerator technology," and the description is substantively accurate in two niches: proton therapy, where it holds roughly 42% of the installed base of proton therapy rooms and sold 12 of the industry's new rooms in 2025, and cyclotrons for radiopharmaceutical production, where its Cyclone family spans every accelerator-produced isotope from F-18 to Astatine-211. Around these sit three adjacent franchises: Rhodotron/Dynamitron electron-beam and X-ray accelerators for medical-device sterilisation, radiation-therapy and imaging quality-assurance (Dosimetry), and an expanding nuclear-medicine "ventures" portfolio led by its equity stake in PanTera (Actinium-225). After a decade of thin margins, IBA is in a profitability turnaround: FY2025 revenue reached a record EUR 620 million, Proton Therapy returned to positive adjusted EBIT, and management targets around 10% adjusted EBIT margin by 2028. The investment case rests on converting a EUR 1.6 billion backlog profitably while capturing option value in alpha-emitter radioisotopes.


What IBA does

IBA designs, manufactures, installs and services particle accelerators and associated systems, and applies that technology in medicine and industry. Since FY2025 it reports in two segments plus a corporate/ventures layer:

IBA Clinical: Proton Therapy (Proteus®ONE and Proteus®PLUS systems, upgrades, restorations, and long-term operations & maintenance contracts) and Dosimetry (quality-assurance hardware and software for radiation therapy, proton therapy and medical imaging).

IBA Technologies: RadioPharma Solutions (RPS) (cyclotrons, targets, radiochemistry synthesisers including the newly acquired ORA NEPTIS® line, consumables, facility design) and Industrial Solutions (Rhodotron® and other electron-beam/X-ray accelerators for sterilisation, food irradiation and materials processing).

IBA Corporate / Ventures: equity-accounted or minority investments: PanTera (Ac-225 production, ~35% at end-2025, ~31% expected after the final Series A tranche), a multi-ion (carbon) accelerator venture (40%), mi2-factory (power semiconductors, 15%), and the newly created Ekalia joint venture with Framatome (Astatine-211).

The company's own description (paraphrased from FY2025/H1 2026 releases)

IBA presents itself as the leading supplier of equipment and services for proton therapy, which it positions as one of the most advanced radiotherapy modalities, and also for industrial sterilisation, radiopharmaceuticals and dosimetry. It emphasises its Louvain-la-Neuve base, roughly 2,300 employees and its B Corp certification. Strategically, the FY2025 presentation frames 2025 as an "inflection point" at which the group shifts toward recurring, profitable growth beyond project cyclicality.

Business and revenue model

Revenue mix item (EUR Mn)FY2024FY2025
Proton Therapy equipment89.4202.7
Proton Therapy services123.4131.7
Dosimetry net sales (product-dominated)65.965.7
IBA Technologies equipment188.8182.7
IBA Technologies services34.842.1
Group total net sales498.2620.2

IBA's model is a capital-equipment-plus-annuity model. Large equipment contracts (a single Proteus®ONE room including multi-year maintenance typically sells for EUR 35–45 million in Europe, or USD 45–55 million in the US; a Cyclone® KIUBE cyclotron for EUR 2.5–5 million) are recognised over time on a percentage-of-completion basis. Each installed system then generates multi-year service revenue — PT operations & maintenance contracts that can run 10+ years, and annually invoiced service contracts in Technologies.

Source: IBA FY2025 results presentation (FY2024 restated for new segmentation). Segment totals include inter-segment eliminations (Clinical reported 395.3 vs PT+Dosimetry 400.0).

On this basis, explicitly identified service revenue (PT services + Technologies services) was EUR 173.8 million in FY2025, or ~28% of group sales, versus ~32% in FY2024 — the share fell because equipment conversion accelerated, not because services shrank (PT services +7%, Technologies services +21%). Subscription and licensing revenues are not separately disclosed and appear immaterial; software is embedded in Dosimetry and PT offerings.

Value-chain position and customers

Customer typeSegmentExamples (disclosed)
Academic medical centres and cancer centresProton TherapyMD Anderson (3 Proteus®ONE retrofit), Duke Health (2 Proteus®ONE), University of Pennsylvania, MGH (system restoration)
Public health systems / ministriesProton TherapySpanish Ministry of Health (10-system order), IPO-Porto (Portugal's national PT centre)
Private / philanthropic hospital groupsProton TherapyMacKay Memorial Hospital (Taiwan), Fundação Severino Sombra (Brazil)
Radiotherapy and imaging departmentsDosimetryHospitals and OEM partners globally
Radiopharmacy networks and radiopharma developersRadioPharma SolutionsTelix/RLS (4 KIUBE), Jubilant Radiopharma (5 KIUBE), SpectronRx, an unnamed global producer (12 KIUBE 300), IRE
Contract sterilisers and medical-device makersIndustrial SolutionsNot individually named in materials reviewed; Chinese X-ray contracts cited

IBA sits at the OEM/system-integrator layer: it designs accelerators (cyclotrons, synchrocyclotrons, Rhodotrons), sources components (magnets, RF, gantries, imaging, third-party equipment — the reason for the IFRS 15 principal-treatment change), integrates, installs and services. In nuclear medicine it is moving downstream into radiochemistry (ORA acquisition), consumables, and via ventures into isotope supply (PanTera Ac-225; Ekalia At-211).

End-markets

Oncology (proton therapy; radioligand/targeted alpha therapy supply chain), diagnostic imaging (PET tracers, including neurology and cardiology "white spaces"), medical-device sterilisation (conversion from ethylene oxide and Cobalt-60 gamma to e-beam/X-ray), food irradiation/phytosanitary, polymer cross-linking, and emerging environmental applications (PFAS destruction R&D). Through mi2-factory, IBA has an indirect exposure to silicon-carbide power semiconductors.

Independent characterisation

IBA is best understood as a mid-cap, project-driven medtech capital-goods company whose earnings power has been structurally suppressed by legacy low-margin proton therapy contracts, inflation on fixed-price backlogs, and working-capital-heavy delivery of large public projects (Spain, China). The FY2025–H1 2026 data show the turnaround is real at the operating line (PT adjusted EBIT from -12.1 in FY2024 to +12.3 in H1 2026 alone) but cash conversion lags (operating cash flow negative in both FY2024 and FY2025; net debt rose to 81 at June 2026). Strategic optionality is disproportionately concentrated in nuclear medicine, where the RPS franchise and PanTera stake could be worth a substantial portion of the current market capitalisation.

Strategy

Stated strategy (themes from the Capital Markets Day framework reused in FY2025 and H1 2026 presentations)

IBA organises its strategy around three axes applied to each business unit, plus a ventures layer:

  1. Increase technology penetration in core markets — in PT, via clinical evidence (MD Anderson Level 1 evidence; ASTRO model policy update placing oropharyngeal cancer in Group 1) and product innovation (DynamicARC®, ConformalFLASH®, AdaPTInsight XR); in Dosimetry, via a combined imaging + RT QA portfolio; in Industrial, via accelerator-based sterilisation replacing EtO and gamma; in RPS, via diagnostic "white spaces" (neurology, cardiology).

  2. Expand in high-potential geographies — Asia (especially China), US leadership, emerging markets.

  3. Expand along the value chain — PT service profitability and heavy-particle modalities; Dosimetry QA value-chain share via acquisitions (PhantomX) and partnerships; Industrial services and new applications (polymers, phytosanitary, PFAS); RPS theranostics (Ac-225, At-211) and radiochemistry/consumables (ORA, CASSY®).

  4. Capital-light ventures — "additional growth via capital-light investments into new ventures (e.g., PanTera, mi2-factory)."

The RPS unit has articulated an explicit repositioning from equipment supplier to "precision oncology enabler" — integrated isotope supply, GMP manufacturing and CDMO-type partnerships with oncology centres.

Strategic initiatives in the last 24 months

InitiativeDateDescriptionStatus
New segmentation and IFRS 15 changeMar 2025Clinical/Technologies structure; principal treatment of third-party equipmentImplemented
SAP S/4 ERP upgrade2025–H1 2026Group ERP migration (EUR 5.3 million one-off cost in FY2025; EUR 2.1 million in H1 2026)Completion targeted H1 2026; invoicing delays noted
PanTera scale-up2025–2028Weekly Ac-225 production, cGMP recognition, commercial plant groundbreaking (Oct 2025), TerraPower/IRE expansion (May 2026)New line end-2027; large-scale centre 2028
ORA acquisitionDec 2025Radiochemistry synthesisers; integration and portfolio optimisation under wayIntegrating
PhantomX acquisition2,025AI-enabled QA phantoms for DosimetryCompleted
Refinancing2,025EUR 125 million bank package (press release) / EUR 135 million total package incl. EUR 10 million subordinated loan (presentation)Closed
Dosimetry cost programmeMar 2026Reorganisation to realign cost basePartial offset expected H2 2026
Product launches2025–2026DynamicARC® MVP, CASSY®, myQA® Blue Phantom³, myQA® StarTrack³, AdaPTInsight XR, Rhodotron® LITE, Cyclone® iKureLaunched
Ekalia JV (At-211) with FramatomeOct 2026 (MoU 2024–25)International network of At-211 production sites; first site Nantes area by ~2028JV formed
Accelerate.EU2025–2026EU IHI project coordinated by IBA and Jules Bordet Institute; first At-211 pilot study in 2026Ongoing
Leadership transitionJun 2026De Romrée operational lead; Legrain strategic steeringImplemented
Share buyback for LTIPFeb–Jun 2026400,000 sharesCompleted

Sustainability commitments

B Corp recertification (score 118), first CSRD report published, >90% renewable electricity, Scope 1 & 2 decarbonisation on track toward a net-zero operations target by 2030, ESG screening of >50% of spend, Oncia Community patient-support initiative.

Medium-term financial targets and guidance

TargetValueStatus (as of Aug 2026)
FY2025 guidance: Group adjusted EBIT≥ EUR 25 million; PT adjusted EBIT positiveDelivered: EUR 27.4 million; PT EUR 10.2 million
FY2026 guidance: Group adjusted EBIT≥ EUR 32 millionReiterated (May and Aug 2026); H1 2026 EUR 17.6 million
2024–2028 revenue CAGR5–7%, front-loaded after high-growth periodReiterated
OpExUp to 30% of sales p.a.28.7% in H1 2026
Adjusted EBIT margin~10% of revenue by 20284.4% FY2025; 5.4% H1 2026
Longer-term aspiration~40% gross margin and ~10% EBIT margin (per H1 2026 call summary on Investing.com; not in the press release)Aspirational
Net financial positionImprove over 2027Net debt 81 at June 2026

Analyst arithmetic: 5–7% CAGR from FY2024's 498.2 implies FY2028 revenue of ~605–653; FY2025 already reached 620, so the outlook implies relatively flat-to-modest revenue in 2026–2028 with margin expansion doing the work. 10% of ~630 implies ~EUR 63 million adjusted EBIT by 2028.

Products & Services

IBA Clinical — Proton Therapy

Product / serviceDescription and capabilitiesTarget customerLaunch / latest versionPricing (if disclosed)
Proteus®ONE (brand of Proteus®235)Compact single-room proton therapy solution built around a superconducting synchrocyclotron and compact gantry; pencil-beam scanning; image guidance; designed to integrate future upgrades. EU MDR certificate obtained for Proteus®235 in 2025Hospitals and cancer centres wanting a single-room or multi-room modular deploymentFirst clinical use ~2014 (not re-verified); continuously upgradedEUR 35–45 million per system incl. multi-year maintenance (Europe/Asia/LatAm); USD 45–55 million in the US (2025–2026 releases)
Proteus®PLUSMulti-room proton therapy centre based on the C235 isochronous cyclotron serving several gantry and fixed-beam roomsLarge academic and national centresLong-standing platform; restoration offers for legacy sitesNot disclosed per contract
DynamicARC®Proton arc therapy solution (rotational delivery) — minimum viable product launched in 2025; still described as in developmentExisting and new Proteus usersMVP 2025—
ConformalFLASH®Ultra-high dose-rate (FLASH) proton delivery; FDA Investigational Device Exemption approval for first-in-human trial obtained in H1 2026; research agreements with Kansas (KUMC) and others since 2023Research and academic centresFDA IDE 2026—
AdaPTInsight XRImaging upgrade for adaptive proton therapy launched in H1 2026Installed base2,026—
System restoration / upgradesFull-system restoration of legacy Proteus®PLUS sites to modern standards (first contract MGH, 2023; restoration begun 2025)Ageing installed base2023–2025—
Operations & maintenance (O&M)Multi-year service contracts; 7 renewals in 2025; PT services backlog EUR 784 million at end-2025All operating sites (45 at end-2025; 47 at mid-2026)OngoingEmbedded in system pricing

China: IBA reports that NMPA clinical trials met all primary endpoints (H1 2026) and has a collaboration agreement with CGN Medical Technology; CGN appears in IBA's H1 2026 new-room market share chart via that collaboration.

IBA Clinical — Dosimetry

Product / serviceDescriptionTarget customerLatest version year
myQA® platformIntegrated QA software ecosystem linking detectors, phantoms and data management for RT, PT and imagingRadiotherapy physics departmentsOngoing
myQA® Blue Phantom³Water-phantom beam scanning system for linac/proton beam commissioningRT/PT physicists2025 release
myQA® StarTrack³Detector array for QA; released at ESTRO 2026RT physicists2,026
Linac QA detector (fast, high-resolution)New detector presented at a 2026 conference (per Q1 2026 update)RT physicists2,026
QUASAR® phantoms (Modus QA)Anthropomorphic and motion phantoms; QUASAR® MR simulation phantom launched for RT marketRT and MR-sim usersQUASAR MR-sim 2025
PhantomX phantomsAcquired in 2025 to enable AI-based quality assuranceImaging and RT QAAcquisition 2025
Proton therapy QADedicated PT dosimetry tools; growing share of Dosimetry backlogPT centresOngoing
Medical imaging QAQA for diagnostic X-ray/CT; under competitive and pricing pressureImaging departmentsOngoing
IBA Dosimetry Academy / servicesTraining, calibration and serviceAll customersOngoing

IBA Technologies — RadioPharma Solutions

ProductKey specification (energy / beam current / last major redesign)UsePricing
Cyclone® KEY9.2 MeV / 100 µA / 2022Compact, in-hospital F-18 and short-lived PET isotopes—
Cyclone® KIUBE (180 / 300)18 MeV / 300 µA / 2016; KIUBE 300 can produce up to 35 Ci F-18 in a two-hour dual-beam run; fleet availability >97% (IBA)High-volume PET radiopharmacies (F-18, Ga-68, Zr-89, C-11)EUR 2.5–5 million depending on configuration
Cyclone® 30XP15–30 MeV / 500 µA / 2010Multi-particle research and SPECT/PET isotopes—
Cyclone® 7030–70 MeV / 750 µA / 2013High-energy isotope production (e.g., Sr-82, Ge-68)—
Cyclone® IKON13–30 MeV / 1,500 µA / 2021High-energy, high-current industrial isotope production (installed at IRE, Belgium; ordered by PET Pharm Bio, Taiwan)—
Cyclone® iKure28.5–29.5 MeV / 2 x 100 µA (alpha) / 2026Purpose-built for industrial-scale Astatine-211; launched at SNMMI 2026—
Nirta® targets (incl. HCFT)Helium-cooling-free F-18 targetsCyclotron usersRecent
NEPTIS® synthesisers (ORA)Fully automated PET radiochemistry modules; ~600 units installed; NEPTIS® xSeed™ for method development, NEPTIS® NaF and othersPET drug manufacturersAcquired Dec 2025
CASSY®New compact radiochemistry synthesiser platform launched 2025Radiopharmacies2,025
Synthera® (legacy IBA radiochemistry)Automated synthesis modulesRadiopharmaciesLegacy (portfolio optimisation with ORA under way)
IntegraLab®Turnkey radiopharmacy facility design and integrationNew production sitesOngoing
Consumables and IBA Kare portalCassettes/reagent kits; online customer portal for KIUBE usersInstalled baseOngoing

IBA Technologies — Industrial Solutions

ProductDescriptionTargetLatest version
Rhodotron® (TT series) e-beam / X-rayHigh-power, high-energy electron accelerators; X-ray conversion for pallet-scale sterilisation; first large-scale X-ray and the world's largest e-beam installations accepted in H1 2026Contract sterilisers, medical-device OEMsOngoing
Rhodotron® LITELower-power X-ray Rhodotron, dual 5/7 MeV, competitive with 1–1.5 MCi gamma centres, aimed at gamma operators, new entrants and in-house sterilisationSmaller sterilisation sites, food irradiationLaunched 2026
Dynamitron® / low-energy e-beamLower-energy electron accelerators for materials processingPolymer/cable/industrial usersLegacy line (details not re-verified)
Rhodotron® for isotopesRhodotron used by PanTera for photonuclear Ac-225 production from Ra-226Isotope producersOngoing
Customer Care / services ("Beyond™" brand on IBA Industrial site)Service, upgrades, uptime programmesInstalled baseOngoing
New applications R&DPFAS destruction ("PFAS-Blaster"), polymer modification pilots, phytosanitary treatmentEnvironmental/industrialDevelopment stage

Financial Narrative

Basis warning: FY2021–FY2022 are on the pre-IFRS 15 change basis; FY2023 is restated (466.7) — original reported FY2023 revenue was 428.7. Adjusted EBIT = REBIT for earlier years.

Income statement

Sources: FY2022 release (FY2021–22 sales, gross margin 34.4%/35.1%, REBIT, net result); FY2023 release (REBIT, REBITDA 19.3 on original 428.7 basis, net result); FY2024 release (restated FY2023 revenue 466.7); FY2025 release/presentation. FY2021 gross profit and FY2021 REBITDA derived from disclosed margins (34.4% and 7.9%); FY2022 gross profit derived from 35.1%. FY2021–FY2022 EPS derived from net result / ~29.1–29.2 million weighted shares (analyst estimate); FY2023 EPS per Digrin aggregator. FY2021 dividend derived (FY2022 EUR 0.21 described as +10%). FY2023 dividend EUR 0.17 per 2024 AGM notice; FY2024 EUR 0.24 per 2025 AGM notice; FY2025 EUR 0.25 per 2026 AGM notice. Diluted EPS is not disclosed in the materials reviewed and is assumed close to basic given limited dilution.

Margins and growth

FY2023 growth (18.7%) is on the original basis (428.7 vs 361.3). FY2023 adjusted EBITDA margin computed on restated revenue (19.3/466.7). Discrepancy: the FY2024 release reported FY2024 gross margin of 33.3%; the FY2025 presentation shows restated FY2024 gross margin of 33.7% (new segmentation restatement).

Revenue CAGR: FY2021–FY2025 ≈ 18.6% p.a. (mixed accounting basis — overstated by the IFRS 15 change); FY2023R–FY2025 ≈ 15.3% p.a. (like-for-like basis).

Commentary. Revenue nearly doubled over four years, driven first by Other Accelerators (Industrial + RPS) in 2022–2024 (sterilisation capacity investment post-COVID; RPS growth) and then by Proton Therapy backlog conversion in 2025 (PT sales +57%, nine rooms delivered). Margin progression has been non-linear. The FY2023 trough reflected three PT-specific issues the company explicitly cited: delays converting Proteus®PLUS projects in China, a mix of older low-margin contracts, and inflation/FX on fixed-price backlog. Gross margin has trended down from ~35% (FY2022) to 32.2% (FY2025), partly mechanically (IFRS 15 grossing-up of third-party equipment depresses percentage margins) and partly due to legacy low-margin PT projects. The H1 2026 gross margin recovery to 33.7% (vs 29.5% in H1 2025) is the first clear evidence that newer, better-priced PT contracts and service scale are flowing through. Operating leverage is the dominant profit driver: OpEx grew 14% in FY2025 against 24% revenue growth, falling to 28% of sales, within the ≤30% framework.

Interim P&L (latest)

Source: IBA H1 2026 presentation appendix. H1 2025 EPS derived (analyst). Below-adjusted-EBIT items in H1 2026: ERP upgrade -2.1, Dosimetry restructuring -1.6, other -1.1; forex -1.0; Argentina hyperinflation impact on Buenos Aires PT project.

Bridge from Adjusted EBIT to net profit, FY2025

Source: FY2025 presentation (figures as presented; minor rounding). Analyst note: ~EUR 7.2 million of FY2025 pre-tax profit was a non-cash revaluation gain on PanTera — underlying net profit excluding it would have been materially lower.

Balance sheet

Sources: FY2025 presentation (FY2024–25 balance sheets); FY2022 and FY2023 results releases (gross and net cash); FY2023 total assets and equity from Google Finance aggregator. Company "net working capital" (operating definition) was -89 (2023), -64 (2024), -21 (2025) per H1 2026 presentation.

Commentary. The defining balance-sheet trend is the erosion of IBA's historical net cash (117 at end-2022) into net debt (58 at end-2025; 81 at mid-2026). This is not driven by losses but by working capital: advance billings (contract liabilities) have unwound from ~298 to ~218 as large projects matured, while contract assets and inventories grew with the Spanish (10-system) and Chinese PT projects. The H1 2026 increase was amplified by IBA's SAP S/4 ERP migration, which changed how procurement progress is recognised (equipment held in inventory until later allocation; ~EUR 50 million of offsetting accruals in payables) and temporarily delayed invoicing. Management expects improvement from H2 2026 with acceleration in 2027 as Spanish deliveries advance. Equity remains thin relative to the balance sheet (equity/assets ~16% at mid-2026), and goodwill/intangibles rose with ORA and PhantomX.

Cash flow

Sources: FY2025 presentation; FY2023 OCF from Google Finance aggregator.

Commentary. Cash generation before working capital is improving in line with EBITDA (30.1 in FY2025 vs 17.8 in FY2024), but has been entirely absorbed by working-capital build. Free cash flow has been negative for two consecutive years. Capex is modest (~2% of sales), confirming an asset-light manufacturing model; the "capital-light" stance extends to ventures, which are funded via third-party equity (PanTera Series A) rather than IBA's balance sheet.

Key ratios

All ratios are analyst calculations from IBA disclosures except the company net leverage ratio. Cash conversion cycle not publicly disclosed. Company net leverage ratio rose to 1.14x at 30 June 2026.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentBusiness unitsContents

IBA Clinical

Proton Therapy; Dosimetry

Proteus®ONE, Proteus®PLUS, upgrades (DynamicARC®, ConformalFLASH®, AdaPTInsight), restorations, O&M services; myQA® platform, phantoms (incl. QUASAR® via Modus QA), imaging QA, PhantomX AI-QA phantoms

IBA Technologies

RadioPharma Solutions; Industrial Solutions

Cyclone® KEY/KIUBE/30XP/70/IKON/iKure cyclotrons, Nirta® targets, Synthera/CASSY®/NEPTIS® radiochemistry, consumables, IntegraLab® design; Rhodotron® e-beam/X-ray (incl. Rhodotron® LITE), services

Corporate / Ventures

n/a (not a reporting segment)

Group costs; equity-accounted PanTera; minority venture stakes

Segment net sales (EUR Mn)

Segment net sales (EUR Mn)FY2024FY2025

IBA Clinical

274.6395.3

IBA Technologies

223.5224.9

Group total

498.2620.2

Business-unit net sales (EUR Mn)

Business-unit net sales (EUR Mn)FY2024FY2025

Proton Therapy

212.8334.3

Dosimetry

65.965.7

IBA Technologies (RPS + Industrial combined)

223.5224.9

Adjusted EBIT (EUR Mn)

Adjusted EBIT (EUR Mn)FY2024FY2025

Proton Therapy

-12.110.2

Dosimetry

4.12.6

IBA Technologies

30.620.0

Corporate / eliminations (derived)

-5.3-5.4

Group Adjusted EBIT

17.327.4

Adjusted EBIT margin (%)

Adjusted EBIT margin (%)FY2024FY2025

Proton Therapy

-5.73.0

Dosimetry

6.23.9

IBA Technologies

13.78.9

Group

3.54.4

Revenue by Segment (%) and Segment Margins & Growth (%)

Metric (%)FY2024FY2025

IBA Clinical share of group sales

55.163.7

IBA Technologies share of group sales

44.936.3

IBA Clinical YoY growth

—44

IBA Technologies YoY growth

—1

Proton Therapy YoY growth

—57

Dosimetry YoY growth

00

Revenue by Segment

Segment metric (EUR Mn)H1 2025H1 2026

IBA Clinical net sales

189.5196.8

Proton Therapy net sales

154.8167.7

— PT equipment

90.8101.7

— PT services

64.066.0

Dosimetry net sales

34.830.8

IBA Technologies net sales

115.4127.0

— Technologies equipment

95.5106.6

— Technologies services

19.920.3

PT Adjusted EBIT

-2.212.3

Dosimetry Adjusted EBIT

2.3-0.5

Technologies Adjusted EBIT

13.18.2

Group Adjusted EBIT

10.617.6

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Interim margin (%)

Interim margin (%)H1 2025H1 2026

PT Adjusted EBIT margin

-1.47.3

Dosimetry Adjusted EBIT margin

6.5-1.7

Technologies Adjusted EBIT margin

11.36.5

Revenue by Segment (Annual)

Old-basis metric (EUR Mn)FY2023FY2024

Proton Therapy net sales (old perimeter, IFRS 15 restated)

239.6242.1

Proton Therapy REBIT

-23.4-21.5

Dosimetry net sales

65.965.9

Dosimetry REBIT

6.14.1

Revenue by Segment (FY2021–FY2025)

Equipment order intake (EUR Mn)FY2021FY2022FY2023FY2024FY2025

Proton Therapy

141281117106250

Dosimetry

5067676660

IBA Technologies

87175104149142

Group total

278523288321452

Revenue by Segment by Equipment Order Intake

Equipment order intake (EUR Mn)H1 2025H1 2026

Proton Therapy

23112

Dosimetry

3136

IBA Technologies

5328

Group total

107176

Income statement (EUR Mn)

Income statement (EUR Mn)FY2021FY2022FY2023FY2024FY2025

Revenue

313.0361.3466.7498.2620.2

Gross profit

107.7126.8—168.1199.6

Operating expenses (S&M + G&A + R&D)

———150.8172.2

Adjusted EBIT (REBIT)

14.511.16.417.327.4

Adjusted EBITDA (REBITDA)

24.721.619.332.049.4

Profit before tax

———14.918.8

Net result

3.96.1-9.19.312.7

EPS basic (EUR)

0.130.21-0.310.320.43

Dividend per share for the year (EUR, gross)

0.190.210.170.240.25

Margin / growth (%)

Margin / growth (%)FY2021FY2022FY2023FY2024FY2025

Gross margin

34.435.1—33.732.2

Adjusted EBIT margin

4.63.11.43.54.4

Adjusted EBITDA margin

7.96.04.16.48.0

Net margin

1.21.7-2.01.92.1

Revenue growth YoY

—15.418.76.724.5

OpEx as % of sales

———30.327.8

Income Statement and Margin Analysis (%)

Interim P&L (EUR Mn)H1 2025H1 2026

Revenue

304.9323.7

Gross profit

90.0108.9

Selling & marketing

15.917.0

General & administrative

32.339.4

Research & development

31.236.4

Adjusted EBIT

10.617.6

Reported EBIT

7.012.8

Adjusted EBITDA

16.426.6

Financial result

-5.0-2.6

Share of equity-accounted results

-0.82.1

Profit before tax

1.212.3

Tax

-3.8-3.0

Net result

-2.69.3

EPS basic (EUR)

-0.090.32

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement

Item (EUR Mn)FY2025

Adjusted EBIT

27.4

ERP upgrade implementation

-5.3

Other operating result

0.7

Other items

-1.2

PanTera revaluation gain

7.2

Equity method result (PanTera)

-0.9

Financial result (incl. forex -3.3, Argentina -1.9/-1.7, interest/other -1.6)

-8.4

Profit before tax

18.8

Tax

-6.0

Net profit

12.7

Balance Sheet

Balance sheet (EUR Mn)FY2022FY2023FY2024FY2025

Total assets

—597.5616.1690.6

Cash and cash equivalents

158.0109.372.264.7

Short-term borrowings + current financial debts

——11.532.2

Long-term borrowings

——3.555.3

Lease liabilities (current + non-current)

——28.729.3

Net debt (negative = net cash), company definition

-117.0-67.7-33.558.0

Total equity

—106.2110.9127.2

Goodwill and other intangibles

——25.743.1

Inventories

——152.8135.4

Contract assets

——77.0113.3

Contract liabilities (advance billing)

——298.4234.1

Working capital (current assets – current liabilities)

——-21.3-3.1

Balance Sheet (FY2025–H1 2026)

Interim balance sheet (EUR Mn)FY2025H1 2026

Total assets

690.6753.9

Cash and cash equivalents

64.743.6

Current borrowings

32.229.7

Non-current borrowings

55.360.1

Net debt (company)

58.081.0

Equity

127.2119.2

Inventories

135.4167.2

Contract assets

113.3148.9

Trade payables

119.9179.2

Contract liabilities

234.1217.9

Cash flow (EUR Mn)

Cash flow (EUR Mn)FY2023FY2024FY2025

Net cash flow before working capital

—17.830.1

Change in working capital

—-25.5-52.9

Operating cash flow

12.0-10.6-25.7

Capital expenditure

—-7.4-12.7

Free cash flow (OCF + capex)

—-18.0-38.4

M&A and other investing

—-6.4-22.6

Dividends paid

—-4.9-7.1

Treasury share purchases

——-6.3

Net borrowing / (repayment)

—-3.776.3

Interim cash flow (EUR Mn)

Interim cash flow (EUR Mn)H1 2025H1 2026

Net cash flow before working capital

7.418.2

Change in working capital

-43.1-25.6

Operating cash flow

-37.3-7.1

Capital expenditure

-5.2-4.3

M&A and other investing

-7.4-3.1

Net borrowing

27.32.2

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025

ROE (%; net result / average equity)

—10.7

ROA (%; net result / average total assets)

—1.9

ROIC (%; analyst estimate: adj. EBIT after 32% effective tax / (equity + net debt))

—10.1

Current ratio (x)

0.950.99

Debt (incl. leases) / equity (x)

0.390.92

Net debt / adjusted EBITDA (x; reported net debt)

—1.17

Company net leverage ratio (net senior debt / LTM adj. EBITDA, x)

—0.83

Interest coverage (adj. EBIT / bank interest & other, approx., x)

—17

Asset turnover (x; revenue / average assets)

—0.95

Geographic Revenue

Region (% of group equipment order intake, excl. upgrades)FY2021FY2022FY2023FY2024FY2025

Americas

4126455527

EMEA

1956432030

APAC

4018132544

Geographic Revenue (FY2025–H1 2026)

Proton Therapy sitesFY2025H1 2026

Americas — operating

1719

Americas — in installation

35

Americas — in production

76

EMEA — operating

1717

EMEA — in installation

23

EMEA — in production

1415

APAC — operating

1111

APAC — in installation

33

APAC — in production

1414

Total sites

8893

Valuation Snapshot

MetricValueSource

Last price (16 Oct 2026)

EUR 16.44

Zonebourse/TradingSat

52-week range (as of Aug 2026)

EUR 9.90 – 17.76

Google Finance

Market capitalisation

~EUR 498 million

Analyst calculation

Average daily volume

~28,000 shares (Aug 2026)

Google Finance

Free float (unnotified)

~42% of shares

IBA structure (Nov 2025)

Reference prices (EUR)

Date

Price

Buyback trades

9–13 Feb 2026

15.20 average

Buyback trade

27 Mar 2026 (FY2025 results day)

12.78 average

Block purchase

8 Jun 2026

16.34

Close

3 Aug 2026

15.94

Close

16 Oct 2026

16.44

Valuation Multiples

MultipleIBABasis

P/E (trailing)

~20x

Price 16.44 / TTM EPS ~0.80–0.84 (FY2025 0.43 + H1 2026 0.32 – H1 2025 -0.09)

EV / Sales (trailing)

~0.9x

EV ~579 (market cap 498 + net debt 81) / TTM revenue ~639

EV / Adj. EBITDA (trailing)

~9.7x

TTM adj. EBITDA ~59.6

EV / FY2026 guided Adj. EBIT

~18x

≥32 guidance

P/B

~4.2x

Equity 119.2 (June 2026)

Dividend yield

~1.5%

EUR 0.25 / 16.44

Dividend per share (EUR, gross, by fiscal year)

Dividend per share (EUR, gross, by fiscal year)FY2021FY2022FY2023FY2024FY2025

Dividend per share

0.190.210.170.240.25

Capital Programmes

ProgrammePeriodSizePurposeStatus

2026 buyback

3 Feb – 30 Sep 2026

Up to 400,000 shares (~1.3% of shares)

Cover LTIP obligations

Completed 12 Jun 2026 (400,000 shares)

Debt Facilities

Facility (EUR Mn)CommittedDrawn at 31 Dec 2025

Subordinated loan

1010

Bank 5-year term loan

5030

Bank acquisition term loan

1515

Revolving credit facilities

6025

Total package

13580

Analyst Conclusions

Management guidance

  • FY2026 Group adjusted EBIT of at least EUR 32 million (reiterated 27 August 2026; H1 delivered 17.6, implying ≥14.4 in H2).

  • 2024–2028: revenue CAGR 5–7% (front-loaded), OpEx ≤30% of sales, adjusted EBIT margin ~10% by 2028.

  • Net financial position to improve over 2027 as Spanish PT deliveries progress.

  • Dosimetry cost measures to partially offset headwinds in H2 2026.

Consensus expectations

The single aggregator data point (three analysts, ~USD 21.7 target) implies modest upside; management guidance (≥32 EBIT for FY2026) is the anchor most brokers reference.

Bull case (grounded in data)

  1. Margin convergence to ~10%: PT already at 7.3% adjusted EBIT margin in H1 2026 with gross margin up 4.1 points; if group revenue holds ~EUR 630–650 million and margin reaches 10% by 2028, adjusted EBIT roughly doubles from FY2025.

  2. Nuclear-medicine re-rating: RPS momentum (12-unit KIUBE order, Telix, Jubilant), ORA consumables, Ekalia, and a PanTera stake worth ~EUR 90–100 million at last funding marks could be worth a large share of IBA's ~EUR 500 million market cap.

  3. PT demand inflection from evidence: Lancet Level 1 data and ASTRO policy change support US reimbursement; 2025 was IBA's second-best year ever for rooms sold (12), and H1 2026 PT orders quadrupled (EUR 112 million vs 23).

Bear case (grounded in data)

  1. Cash, not profit, is the binding constraint: FCF negative for two years; net debt rose from 58 to 81 in six months; any slippage in Spanish milestones extends the squeeze.

  2. Order share erosion and lumpy intake: IBA's share of new PT rooms fell to 31% in H1 2026; two-year book-to-bill slid to 0.9x; Technologies book-to-bill 0.7x with Industrial orders depressed until ~2028–29.

  3. Earnings quality and execution: recurring "one-offs" (ERP, restructuring, FX, Argentina), reliance on PanTera revaluation gains in FY2025, and Dosimetry losses suggest reported net profit will lag adjusted EBIT.

Key catalysts and monitorables (next 12 months)

Date / timingCatalystWhat to watch
26 Nov 2026Q3 2026 business updateNet debt trajectory post-ERP; Q3 order intake; Dosimetry
H2 2026PanTera fourth Series A trancheValuation mark vs ~EUR 290 million; IBA stake ~31%
H2 2026–2027Spanish PT delivery milestonesWorking-capital release
18 Mar 2027FY2026 resultsDelivery vs ≥EUR 32 million; FY2027 guidance; dividend
2,027Ekalia site permitting/build; Accelerate.EU At-211 pilotAlpha franchise de-risking
OngoingUS PT orders following ASTRO update; DynamicARC®/ConformalFLASH® progressOrder share recovery
OngoingIndustrial order recovery; Rhodotron® LITE first ordersTechnologies book-to-bill
End-2027 / 2028PanTera new line; large-scale Actinium Production CenterVenture value crystallisation

Analyst verdict

IBA has crossed the most important threshold in its recent history: Proton Therapy, the franchise that defined and long depressed the company, is now profitable on a sustained basis. The evidence is not just the FY2025 swing to EUR 10.2 million adjusted EBIT, but H1 2026's EUR 12.3 million at a 7.3% margin with a recovering gross margin of 33.7% — the signature of legacy contracts rolling off and a 47-site service base gaining scale. Combined with the strongest clinical-evidence tailwind the modality has ever had, the PT franchise now looks like a credible cash generator rather than a perennial drag.

The equity story, however, is no longer only about PT. The most asymmetric value sits in nuclear medicine: a cyclotron range that now reaches industrial At-211, a radiochemistry layer via ORA, and minority stakes in PanTera and Ekalia that are funded largely by partners. At roughly 0.9x EV/sales and ~10x trailing EBITDA, the market is ascribing limited value to these options.

Against this, the balance sheet has turned from a defensive asset into a constraint. Net debt of EUR 81 million is modest in absolute terms, but two years of negative free cash flow, ERP disruption and dependence on milestone timing on large public projects mean that cash conversion — not EBIT — is the variable investors should underwrite. Dosimetry and Industrial Solutions also need to stabilise before margin targets look secure.

On balance, IBA screens as a self-help turnaround with embedded radiopharma optionality. The thesis strengthens materially if FY2026 delivers at least EUR 32 million adjusted EBIT alongside visible net-debt reduction in H2 2026–2027; it weakens if book-to-bill stays below 1.0x and PT share in new rooms fails to recover. Our stance is constructive, conditional on cash delivery.


All derived figures are labelled as analyst calculations.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / recent changePrior roles / notesAge / education

Olivier Legrain

Chief Executive Officer; Vice-Chairman of the Board (since June 2026)

CEO since May 2012; previously Chief Strategy Officer and COO (Jan 2012)

Has led IBA through the PT build-out, the 2023 trough and the 2025 turnaround; now focused on strategic steering

Not disclosed in materials reviewed

Henri de Romrée

Deputy CEO; strategic and operational responsibility for all Group activities (since June 2026)

Deputy CEO since March 2024; previously led IBA Technologies

——

Catherine Vandenborre

Chief Ventures & Corporate Officer (since June 2026); leads partnerships, innovation and cross-functional departments including Finance

CFO and "IBA Corporate Lead" at FY2025 results (March 2026)

——

Christian Matton

Chief Legal Officer

Secretary of 2025 AGM

——

Loïk-Maël Nys

President, IBA RadioPharma Solutions

Quoted as President in October 2026 KIUBE release

Succeeded Charles Kumps (President RPS through at least March 2026); succession date not disclosed

—

Thomas Pevenage

Head of Investor Relations

———

Olivier Lechien

Corporate Communication

———

“—” = not publicly disclosed.

Board of Directors

DirectorRoleNotes

Saint-Denis SA, represented by Pierre Mottet

Chairman

Chairman since 2013 (per succession plan); former IBA CEO (24 years at IBA by 2012)

Olivier Legrain

Vice-Chairman; executive director (CEO)

Appointed Vice-Chairman June 2026

Joyce Hansen

Director (joined June 2026)

~Four decades in industrial microbiology and sterility assurance (Johnson & Johnson)

Dr Stephen Hahn

Director (joined June 2026)

Physician-scientist; former US FDA Commissioner; CEO and Board Chair of Nucleus RadioPharma

Christine Dubus

Independent director; Audit Committee chair (as appointed 2020)

—

Dr Richard Hausmann

Independent director (appointed 2020)

—

Three directors proposed by the IBA Foundation (private trust)

Directors

—

Departed (June 2026)

Sybille van den Hove (chair of Sustainability Board since its creation); Muriel de Lathouwer

—

Board & Management Changes

DateChangeContext

March 2024

Henri de Romrée appointed Deputy CEO

Focus on Other Accelerators performance and future opportunities

~April 2025

CFO Soumya Chandramouli departs (to Novadip)

Catherine Vandenborre subsequently CFO

16–17 June 2026

Joyce Hansen and Stephen Hahn join; van den Hove and de Lathouwer leave

Adds sterilisation and FDA/radiopharma expertise

17 June 2026

Legrain Vice-Chairman; de Romrée full operational responsibility; Vandenborre Chief Ventures & Corporate Officer

Presented as a prepared leadership transition; effectively sets up de Romrée as operational successor

2026 (by October)

Loïk-Maël Nys becomes President of RPS

Replaces Charles Kumps (date not disclosed)

Major Shareholders

HolderShares% of shares% of voting rights

Sustainable Anchorage SRL (anchor/founder-management vehicle, formerly Belgian Anchorage)

6,204,66820.4930.48

Premier Miton Capital

1,815,6056.004.48

Vallcara Limited

1,621,5655.354.00

Institut des Radioéléments (IRE)

1,423,2714.707.03

Belfius Insurance

1,189,1963.935.87

IBA SA (treasury)

962,3293.182.54

Paladin Asset Management

806,5692.661.99

Wallonie Entreprendre

715,4912.363.53

FMR LLC (Fidelity)

579,6501.911.43

NS Partners Europe SA

437,7481.451.08

UCLouvain

426,8851.412.11

BNP Paribas Asset Management

407,9851.351.01

Bayrime SA

265,9370.880.66

Public / free float (unnotified)

12,583,71141.5531.58

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs IBA

Proton therapy

Varian (Siemens Healthineers) — ProBeam®

#2 installed base (~21–22%); deep RT/linac channel and software; stronger balance sheet

Proton therapy

Hitachi

~19% installed base; ~11% of 2025 new rooms; strong in Japan/US academic

Proton therapy

Mevion Medical Systems

~9% installed base; compact single-room; 21% of 2025 and 31% of H1 2026 new rooms; private

Proton therapy

Sumitomo Heavy Industries

Asia-focused proton systems; included in "others"

Proton therapy

ProTom International

5% of 2025 new rooms (Radiance 330)

Proton therapy

CGN Medical Technology

19% of H1 2026 new rooms (counted via collaboration agreement with IBA, per IBA footnote)

Proton therapy / heavy ion

Toshiba Energy Systems, Hitachi (carbon)

Carbon-ion competition to IBA's multi-ion venture

Cyclotrons (RPS)

GE HealthCare (PETtrace)

Major installed base in PET cyclotrons

Cyclotrons (RPS)

Siemens Healthineers (Eclipse)

PET cyclotron and radiopharmacy network synergies

Cyclotrons (RPS)

Sumitomo Heavy Industries

HM-series cyclotrons, strong in Asia

Cyclotrons (RPS)

Best Cyclotron Systems (TeamBest), ACSI

High-energy and medium cyclotrons

Radiochemistry

GE HealthCare (FASTlab), Trasis, Eckert & Ziegler

Synthesiser competition to NEPTIS®/CASSY®

Industrial sterilisation equipment

Mevex, Wasik Associates, NHV Corporation, others

E-beam/X-ray accelerator OEMs; gamma (Cobalt-60) and EtO are substitute technologies

Dosimetry

Sun Nuclear (Mirion Medical)

Leading RT QA competitor

Dosimetry

PTW Freiburg, Standard Imaging, LAP

Detectors, phantoms, QA software

Competitor Detail

Proton therapy installed-room share (%)H1 2026

IBA

42

Varian

21

Hitachi

19

Mevion

9

Others

9

Share of new PT rooms sold (%)

FY2024

IBA

56

Mevion

44

Hitachi

0

ProTom

0

CGN (via IBA collaboration)

0

Peer Comparison FY2025

MetricIBA (FY2025, EUR)Siemens Healthineers — Varian segment (FY Sep-2025, EUR)Mirion Technologies — Medical segment (FY2025, USD)

Revenue

620.2 M

4,081 M

310.8 M (group 925.4 M)

Revenue growth

+24%+6.9%

+3.7% (group +7.5%)

Margin

Adj. EBIT 4.4%

Adj. EBIT margin 13.2–19.7% across FY2025 quarters (Q4: 19.7%)

Operating income 46.9 M (~15.1%)

R&D intensity

10.0% of sales

Not disclosed at segment level

Not disclosed at segment level

Company Snapshot

$699.2M

Revenue

2,300

Employees

1986

Founded

Louvain-la-Neuve, Belgium

Headquarters

SWOT Analysis

Strengths

  • Market leadership in PT: ~42% of installed PT rooms and 63% of 2025 new rooms (12 rooms) per IBA FY2025 presentation.
  • Record visibility: EUR 1.6 billion backlog (EUR 0.78 billion equipment, EUR 0.82 billion services) at end-2025, stable at mid-2026.
  • PT turnaround delivered: PT adjusted EBIT from -12.1 (FY2024) to +10.2 (FY2025) and +12.3 in H1 2026 alone (7.3% margin).
  • Growing annuity: PT services revenue +7% in FY2025; seven O&M contracts renewed; PT services backlog +16% to EUR 784 million.
  • Broadest cyclotron range: six Cyclone platforms from 9.2 MeV to 70 MeV plus alpha-dedicated iKure; KIUBE fleet availability >97%; 12-unit US order (Oct 2026).
  • Valuable venture options at low capital cost: PanTera valued ~EUR 290 million post-money (Aug 2025), IBA ~31–35%; PanTera H1 2026 revenue EUR 13.7 million and EBITDA EUR 6.7 million.
  • Committed, stable shareholder base: ~30% voting control by Sustainable Anchorage plus Belgian institutions, supporting long-horizon strategy.

Weaknesses

  • Low group margins: adjusted EBIT margin 4.4% (FY2025) vs Varian segment margins in the mid-to-high teens.
  • Negative free cash flow: FCF -18.0 (FY2024) and -38.4 (FY2025); OCF -7.1 in H1 2026.
  • Balance-sheet deterioration: from EUR 117 million net cash (FY2022) to EUR 81 million net debt (June 2026); net leverage 1.14x.
  • Dosimetry underperformance: H1 2026 sales -11% and adjusted EBIT -0.5; FY2025 margin down to 3.9% amid pricing pressure and tariffs.
  • Earnings quality: FY2025 PBT of 18.8 included a EUR 7.2 million non-cash PanTera revaluation gain; below-EBIT one-offs (ERP 5.3; FX 3.3) recur.
  • Gross margin dilution: 32.2% in FY2025 vs 35.1% in FY2022, partly from legacy low-margin PT projects.
  • ERP execution issues: S/4 migration caused invoicing delays and a EUR 50 million inventory methodology shift in H1 2026.

Opportunities

  • Reimbursement expansion in the US after ASTRO's model-policy update for oropharyngeal cancer (May 2026 update).
  • Retrofit/replacement cycle: MD Anderson (3 Proteus®ONE retrofit) and MGH restoration show monetisation of ageing installed bases.
  • Alpha-emitter supply chain: Ekalia (At-211, first site ~2028) and PanTera capacity +200% with TerraPower/IRE; >40 Ac-225 trials.
  • New PT geographies: first centres in Portugal and Rio de Janeiro (2026); China NMPA trial endpoints met.
  • Sterilisation substitution: Rhodotron® LITE targets gamma operators facing Cobalt-60 constraints; demand-capacity balance expected ~2028–29.
  • Radiochemistry consumables: ORA's ~600-unit NEPTIS® base plus CASSY® opens recurring consumables revenue (IBA flags a consumable play "to be determined").
  • Next-generation PT tech: DynamicARC®, ConformalFLASH® (FDA IDE) could re-accelerate upgrades and differentiate against Mevion/Varian.

Threats

  • Share loss in new PT orders: IBA's share fell to 31% in H1 2026 with Mevion at 31% and Hitachi/CGN at 19% each.
  • Scale competitors: Siemens Healthineers' Varian (EUR 4.1 billion revenue) and GE HealthCare can bundle PT/RT/PET.
  • Industrial overcapacity persisting: Technologies orders fell to EUR 28 million in H1 2026 (-48%).
  • Macro/FX/tariffs: US and China tariffs and USD/CNY moves already hit Dosimetry and financial result.
  • Project/customer risk: history of customer insolvency (Rutherford) and bad-debt charges; long lead times (2029–2030 starts) expose to hospital financing.
  • Venture execution risk: PanTera large-scale centre only in 2028; competing Ac-225 routes (TerraPower 20x expansion by 2029, reactor-based routes) could compress isotope pricing.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025CFO Soumya Chandramouli leaves to join Novadip as CFOFinance leadership change; Catherine Vandenborre becomes CFO
11 Jun 2025AGM approves FY2024 dividend of EUR 0.24/share (~EUR 7.0 million); PwC appointed for sustainability assuranceDividend up from EUR 0.17
Jun 2025PanTera begins Ac-225 supply for clinical trials and compassionate useVenture becomes revenue-generating
Aug 2025PanTera third Series A tranche (~EUR 290 million post-money); IBA ~35%EUR 7.2 million revaluation gain in FY2025
28 Aug 2025H1 2025 results: sales +40% to 304.9; REBIT 10.6; net loss -2.6; net debt 30Growth strong but cash absorbed by working capital
Oct 2025PanTera full-scale weekly production; groundbreaking of Actinium Production CenterDe-risks venture
Nov 2025Portugal publishes PT tender (later awarded to IBA); Q3 2025 business updatePipeline
15 Dec 2025IBA highlights MD Anderson Phase III H&N trial in The Lancet (reduced toxicity, improved survival vs IMRT)First Level 1 evidence for PT — key reimbursement catalyst
19 Dec 2025ORA acquisitionExpands radiochemistry; EUR 17 million net-debt impact
End Dec 2025MD Anderson selects IBA for three Proteus®ONE (booked in 2025 order intake)Flagship win via competitive RFP
End 2025Telix 4 KIUBE contract signed (announced Mar 2026); EUR 125–135 million refinancing closedRPS momentum; funding secured
27 Jan 2026MacKay Memorial (Taiwan) Proteus®ONE contractFourth Proteus®ONE in Taiwan
2 Feb 2026Buyback launched: up to 400,000 shares to 30 Sep 2026LTIP coverage
Mar 2026Dosimetry reorganisation announcedCost realignment (EUR 1.6 million cost in H1 2026)
20 Mar 2026Telix/RLS four Cyclone® KIUBE 180 announcedUS theranostics manufacturing
27 Mar 2026FY2025 results: record sales 620.2; adjusted EBIT 27.4; net 12.7; FY2026 guidance ≥32; dividend proposal EUR 0.25Guidance beaten; turnaround confirmed
21 May 2026Q1 2026 update: on track; ASTRO updates PT model policy (oropharyngeal cancer to Group 1); 279,188 shares bought backUS reimbursement tailwind
27 May 2026TerraPower Isotopes/PanTera/IRE expansion: PanTera cGMP Ac-225 capacity +200%Venture capacity growth
May 2026myQA® StarTrack³ released at ESTRO 2026Dosimetry portfolio refresh
Jun 2026Cyclone® iKure launched at SNMMI for industrial At-211Alpha-emitter equipment
8 Jun 2026Duke Health two Proteus®ONE (treatments from 2029)US academic expansion
10 Jun 2026AGM; dividend EUR 0.25 approved; directors appointed (incl. three IBA Foundation nominees)Governance
12 Jun 2026Buyback completed at 400,000 sharesCompleted ahead of deadline
17 Jun 2026Leadership transition and Board changes (Hansen, Hahn join)Succession preparation
25 Jun 2026FUSVE (Brazil) Proteus®ONE — first PT centre in Rio de JaneiroLatAm
30 Jun 2026IPO-Porto contract effective: two Proteus®ONE, Portugal's first PTPublic tender win
H1 2026ConformalFLASH® FDA IDE approval; Rhodotron® LITE launch; AdaPTInsight XR launch; China NMPA trials meet endpointsProduct pipeline
Jul 2026CyclHad provides EUR 8 million loan to multi-ion ventureVenture financing
27 Aug 2026H1 2026 results: sales 323.7 (+6%); adjusted EBIT 17.6; net 9.3; orders 176 (+64%); net debt 81Profit up; cash/working capital concern
8 Sep 2026Transparency notification: a holder crosses below 1%Minor ownership change
15 Oct 2026Order for 12 Cyclone® KIUBE 300 for a US national PET network (EUR 2.5–5 million per system list range)Largest single-order cyclotron count disclosed
16 Oct 2026Ekalia JV with Framatome for At-211 announced; shares +1.5% to ~EUR 16.4Second alpha franchise
26 Nov 2026 (scheduled)Q3 2026 business updateNext catalyst

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

8 charts
Income Statement: Revenue & Gross Profit: Revenue rose from EUR 304.9 Mn in H1 2025 to EUR 323.7 Mn in H1 2026.
Ion Beam Applications S.A. — Income Statement: Revenue & Gross Profit
Series (EUR Mn)H1 2025H1 2026
Revenue304.9323.7
Gross profit90108.9

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.